Trials / Completed
CompletedNCT02545738
Antiproteinuric Effects of Liraglutide Treatment
Antiproteinuric Effects of Liraglutide Treatment in Patients With Type 2 Diabetes and Albuminuria: A Randomised, Placebo-Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Steno Diabetes Center Copenhagen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the effect of Liraglutide on albuminuria in type 2 diabetes.
Detailed description
Initial findings point to a clinically significant antiproteinuric effect of liraglutide treatment, possibly independent from blood pressure reduction. The mechanism behind is unclear and the magnitude of albuminuria reduction needs to be verified. Antiproteinuric effects are usually renoprotective and potentially also cardioprotective and may suggest an additional benefit from liraglutide treatment. The aim of this study is to evaluate the magnitude of the antiproteinuric effect of short-term liraglutide treatment (12 weeks) in patients with type 2 diabetes and albuminuria. In addition, possible mechanisms causing the antiproteinuric effect will be explored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liraglutide | active treatment |
| DRUG | placebo | placebo |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2015-09-10
- Last updated
- 2016-08-10
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02545738. Inclusion in this directory is not an endorsement.